Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.

about

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.

Item

http://www.wikidata.org/entity/Q48010137

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Population Pharmacokinetic and ...... Systemic Lupus Erythematosus.

@en

Population Pharmacokinetic and ...... Systemic Lupus Erythematosus.

@nl

type

Item

label

Population Pharmacokinetic and ...... Systemic Lupus Erythematosus.

@en

Population Pharmacokinetic and ...... Systemic Lupus Erythematosus.

@nl

prefLabel

Population Pharmacokinetic and ...... Systemic Lupus Erythematosus.

@en

Population Pharmacokinetic and ...... Systemic Lupus Erythematosus.

@nl

P1476

Population Pharmacokinetic and ...... Systemic Lupus Erythematosus.

@en

P2093

David Roth

http://www.w3.org/2001/XMLSchema#string

Herbert Struemper

http://www.w3.org/2001/XMLSchema#string

Mita Thapar

http://www.w3.org/2001/XMLSchema#string

P2860

The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan

One year in review 2016: systemic lupus erythematosus

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Population pharmacokinetics of therapeutic monoclonal antibodies.

P2888

s40262-017-0586-5

P304

717-728

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-017-0586-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28887801

http://www.w3.org/2001/XMLSchema#string

P932

5973992

http://www.w3.org/2001/XMLSchema#string